Femasys Secures FDA Approval and $12M Financing for FemBloc Trial

Femasys Inc. saw a 25% surge in premarket trading following FDA approval to advance the final phase of its pivotal FemBloc trial, a non-surgical permanent birth control method, marking progress toward potential U.S. market entry. The company secured $12 million in senior secured convertible notes and warrants, with potential proceeds reaching $58 million, to refinance existing debt and support commercialization of its fertility and birth control products. Femasys focuses on minimally invasive women's healthcare technologies, including products for infertility treatment, fallopian tube assessment, and cervical cancer diagnosis. Despite this progress and investor confidence, the company's financial performance remains challenged, with persistent losses and negative cash flow impacting its stock rating. Femasys aims to transform women's health by providing accessible, office-based, non-surgical solutions, reflecting a mission to improve patient care and health economics. The FDA milestone and funding agreement underscore continuing investor support amid ongoing efforts to bring FemBloc and other products to market.